Next Article in Journal
Acute and Long-Term Consequences of COVID-19 on Arterial Stiffness—A Narrative Review
Next Article in Special Issue
Microvasculopathy Evaluated by Dual-Energy Computed Tomography in Patients with Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension
Previous Article in Journal
A Serious Game for the Prevention of Obesity in School Children–Impact of Parent’s Involvement: A Randomized Controlled Trial
Previous Article in Special Issue
Pulmonary Artery Pressure-Guided Telemonitoring Reduced Pulmonary Artery Pressure but Did Not Result in Higher Doses of Guideline-Directed Medical Therapy–Observations from an Advanced Elderly German Heart Failure Cohort
 
 
Article
Peer-Review Record

Beneficial Effects of Pulmonary Vasodilators on Pre-Capillary Pulmonary Hypertension in Patients with Chronic Kidney Disease on Hemodialysis

by Keiji Kimuro, Kazuya Hosokawa *, Kohtaro Abe, Kohei Masaki, Satomi Imakiire, Takafumi Sakamoto and Hiroyuki Tsutsui
Reviewer 1:
Reviewer 2: Anonymous
Submission received: 21 April 2022 / Revised: 20 May 2022 / Accepted: 23 May 2022 / Published: 24 May 2022
(This article belongs to the Special Issue Pulmonary Hypertension: From Bench to Bedside)

Round 1

Reviewer 1 Report

     Kimuro et al. evaluated the effect of pulmonary vasodilators in patients with pulmonary hypertension and end-stage CKD on hemodialysis. This is interesting case series and well executed, but following issues need to be responded.

 

Major concerns

  • Recently, Edmonston et al. showed the prevalence of different PH subtypes and their association with all-cause mortality in patients with CKD including hemodialysis patients (Am J Kidney Dis 2020). The data showed hemodynamic definition of PH was important predictor in patients with PH and CKD. Although the authors in this manuscript mentioned the importance of the definition in the introduction and discussion, the case series does not describe the hemodynamic typing of PH, so we do not know what proportion of patients had Cpc-PH or how many had pre-capillary PH, nor do we know the drug responsiveness of each pathology. Based on such data, it would be presumptuous to describe a treatment strategy as shown in Figure 3. Please show diastolic pressure gradient; DPG of each patient and discuss.
  • Interstitial lung disease also significantly affects pulmonary vascular resistance. Please also describe the presence or absence of interstitial lung disease complications.
  • In the methods, the definition of pulmonary hypertension states that the mean pulmonary arterial pressure is higher than 15 mmHg, but I think it may be a mistake for 20 mmHg.

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

Kimura et al provided a case series of CKD on hemodialysis with pulmonary hypertension treated with pulmonary vasodilators. With their research authors provide an insight on a less explored are of PH. My only suggestion would be on presenting data. they provided 7 patients data which means it is impossible to be normally distributed. So it would be better to represent this data as median and IQR when appropriate. Also decimal points may not be necessary when representing this kind of data.

Best regards

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Round 2

Reviewer 1 Report

The authors addressed my concerns.

 

Back to TopTop